Author: Simon Padbury

Strategy and Marketing Planner, REPROCELL

Press Release: ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

Funding will be used to improve efficiency of induced pluripotent stem cell production

Continue reading 

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.

Continue reading 

Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow

REPROCELL Europe Ltd was pleased to receive a visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017.

Continue reading 

REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018

The SMi Group’s conference on 3D Cell Culture will be held on 21-22 February 2018.The venue is the Copthorne Tara Hotel in Kensington, London, UK.

 Find out more at

REPROCELL Europe’s CSO Professor Stefan Przyborski will chair the first day of the conference.

Continue reading 

Formation of human tissue to improve drug testing and reduce animal research

REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday, at

Continue reading 

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

Continue reading 

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.

Continue reading 

Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)

This following video is from Nicola Sturgeon, First Minister of Scotland's YouTube channel:

Continue reading 

Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

New headquarters strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland. Press release 10th August 2017.

Continue reading 

REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer using techniques such as 3D models, PDX systems and precision-cut tumour slices. Chaired by Professor Gareth Thomas of the University of Southampton, presentations were delivered from, among others, Professor Will Shu and Dr Nick Lesley, who described developments in 3D bioprinting of tumours, and Dr Phil Quinlan of the UKCRC Tissue Directory.

Continue reading